Power3 files patent for protein biomarkers

Power3 Medical has determined the blood serum concentrations of these forty-seven biomarkers in samples from more than 750 neurodegenerative disease patients and normal control subjects. The results have shown that this group of biomarkers are useful in the differential diagnosis of Alzheimer’s disease from normal control individuals, patients with non-Alzheimer’s dementias, and patients with Parkinson’s disease or ALS (Lou Gehrig’s disease).

Steven Rash, CEO of Power3, said: “Power3’s identification of these forty-seven biomarkers, based on our unique, proprietary proteomic discovery platform, is critical to the value of our intellectual property. These biomarkers are essential discoveries that will be used in the development of high-throughput commercial diagnostic tests, monitoring the progress of patients during treatment or clinical trials, and in identifying novel drug targets.”